The aim of the Developmental Core is to provide limited research funds to support preliminary studies by new investigators to Neuro-AIDS as well as established investigators that wish to try novel approaches to the stgdy of CMS infections and/or treatment. The goal is to allow for the generation of initial findings to aid in obtaining R01 support for the investigator and thus bring new investigators and approaches to the field. As in the previous funding period, solicitations for new grant proposals will be made annually, with the anticipation to fund two new applications per year. Applications will be solicited from all disciplines at TSRI as well as from neighboring institutions. Grants will be reviewed by a panel of three outside reviews, with oversight by Drs. Elder and Fox. Grants will typically be funded for two years to be spent at the researcher's discretion, but must include a percentage effort by the investigator. This program has been highly successful in the past, with 12 grants awarded, resulting in 20 publications or manuscripts in submission;4 new NIH grants;and 1 Dana Farber grant. We expect continued success in the next granting period, with a major goal being the increased recruitment of effort from diverse disciplines.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Center Core Grants (P30)
Project #
7P30MH062261-09
Application #
7784477
Study Section
Special Emphasis Panel (ZMH1)
Project Start
2009-03-09
Project End
2011-02-28
Budget Start
2009-03-09
Budget End
2010-02-28
Support Year
9
Fiscal Year
2009
Total Cost
$167,650
Indirect Cost
Name
University of Nebraska Medical Center
Department
Type
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Sathyanesan, Monica; Watt, Michael J; Haiar, Jacob M et al. (2018) Carbamoylated erythropoietin modulates cognitive outcomes of social defeat and differentially regulates gene expression in the dorsal and ventral hippocampus. Transl Psychiatry 8:113
Zhou, Tian; Su, Hang; Dash, Prasanta et al. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151:53-65
Thangaraj, Annadurai; Periyasamy, Palsamy; Liao, Ke et al. (2018) HIV-1 TAT-mediated microglial activation: role of mitochondrial dysfunction and defective mitophagy. Autophagy 14:1596-1619
Kevadiya, Bhavesh D; Ottemann, Brendan M; Thomas, Midhun Ben et al. (2018) Neurotheranostics as personalized medicines. Adv Drug Deliv Rev :
Wiesman, Alex I; O'Neill, Jennifer; Mills, Mackenzie S et al. (2018) Aberrant occipital dynamics differentiate HIV-infected patients with and without cognitive impairment. Brain 141:1678-1690
Periyasamy, Palsamy; Thangaraj, Annadurai; Guo, Ming-Lei et al. (2018) Epigenetic Promoter DNA Methylation of miR-124 Promotes HIV-1 Tat-Mediated Microglial Activation via MECP2-STAT3 Axis. J Neurosci 38:5367-5383
Zhou, Tian; Lin, Zhiyi; Puligujja, Pavan et al. (2018) Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals. Nanomedicine (Lond) 13:871-885
Yang, Lu; Niu, Fang; Yao, Honghong et al. (2018) Exosomal miR-9 Released from HIV Tat Stimulated Astrocytes Mediates Microglial Migration. J Neuroimmune Pharmacol 13:330-344
Lin, Zhiyi; Gautam, Nagsen; Alnouti, Yazen et al. (2018) ProTide generated long-acting abacavir nanoformulations. Chem Commun (Camb) 54:8371-8374
McMillan, JoEllyn; Szlachetka, Adam; Zhou, Tian et al. (2018) Pharmacokinetic testing of a first generation cabotegravir prodrug in rhesus macaques. AIDS :

Showing the most recent 10 out of 374 publications